EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Response to Comments on “Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice”

Kelly George, Allyson Anding

The Journal of Pharmacology and Experimental Therapeutics · 2024

DOI: 10.1124/jpet.123.002080 ↗

Kurz gefasst

Leserbrief in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2024. Verfasst von Kelly George und 1 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic and Lysosomal Storage Disease Research, Rare and Neurologic Diseases Therapeutic Area, Sanofi, Cambridge, Massachusetts kelly.george@sanofi…. Hauptthemen laut MEDLINE: Glycogen Storage Disease Type II, Enzyme Replacement Therapy, Mannosephosphates, alpha-Glucosidases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We thank Dr. Weimer and her colleagues for their comments related to our recent work (Anding et al., 2023) and are grateful for the opportunity to further discuss the importance of efficient lysosomal targeting of enzyme-replacement therapies (ERT) for the treatment of Pompe disease. Patients with Pompe disease have mutations in the gene that encodes for acid α glucosidase (GAA), a lysosomal enzyme necessary for the breakdown of glycogen. The first-generation ERT, alglucosidase alfa, provides a lifesaving therapy for the severe form of the disease (infantile onset Pompe disease) and improves or stabilizes respiratory and motor function in patients with less severe disease (late onset Pompe disease). Despite these gains, significant unmet need remains, particularly in patients who display respiratory and motor decline following years of treatment. Poor tissue uptake and lysosomal targeting via inefficient binding of the cation-independent mannose-6-phosphate (M6P) receptor (CIMPR) in skeletal muscle contributed to this suboptimal treatment response, prompting the development of new ERTs with increased levels of M6P.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycogen Storage Disease Type IIEnzyme Replacement TherapyMannosephosphatesalpha-Glucosidases1-DeoxynojirimycinAnimalsMiceHumansLysosomes

Substanzen

Mannosephosphatesalpha-Glucosidases1-Deoxynojirimycinmannose-6-phosphatemiglustat

Autor:innen und Institutionen

  • Metabolic and Lysosomal Storage Disease Research, Rare and Neurologic Diseases Therapeutic Area, Sanofi, Cambridge, Massachusetts kelly.george@sanofi.com.
  • Metabolic and Lysosomal Storage Disease Research, Rare and Neurologic Diseases Therapeutic Area, Sanofi, Cambridge, Massachusetts.

Zitieren

APA

George, K., & Anding, A. (2024). Response to Comments on “Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice”. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.123.002080

Vancouver

George K, Anding A. Response to Comments on “Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice”. The Journal of Pharmacology and Experimental Therapeutics. 2024. doi:10.1124/jpet.123.002080

BibTeX
@article{George2024,
  author = {George, Kelly and Anding, Allyson},
  title = {Response to Comments on “Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice”},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2024},
  doi = {10.1124/jpet.123.002080}
}
Kostenlos starten →